Center for Scientific Review; Notice of Closed Meetings, 44671 [05-15246]
Download as PDF
Federal Register / Vol. 70, No. 148 / Wednesday, August 3, 2005 / Notices
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: July 26, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–15242 Filed 8–2–05; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice
is hereby given of the following
meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special emphasis Panel, Member
Conflict: Tumor Cell Biology and
Microenvironment.
Date: August 2, 2005.
Time: 11 a.m. to 1 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone conference call).
Contact Person: Sharon K. Gubanich, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6204,
MSC 7804. Bethesda, MD 20892. (301) 435–
1767. gubanics@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Hyperaccelerated Award/Mechanisms in
Immunomodulation Trials.
Date: August 2, 2005.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive. Bethesda, MD 20892.
(Telephone conference call).
Contact Person: Samuel C. Edwards, PhD,
Scientific Review Administrator, Center for
VerDate jul<14>2003
15:22 Aug 02, 2005
Jkt 205001
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4200,
MSC 7812, Bethesda, MD 20892. (301) 435–
1767. edwardss@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel,
Dermatological Sciences Special Emphasis
Panel.
Date: August 8, 2005.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive. Bethesda, MD 20892.
(Telephone conference call).
Contact Person: Aftab A. Ansari, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4108,
MSC 7814, Bethesda, MD 20892. (301) 594–
6376. ansaria@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Entamoeba Metabolism and
Virulence.
Date: August 16, 2005.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone conference call).
Contact Person: Joseph D. Mosca, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5158,
MSC 7808, Bethesda, MD 20892. (301) 435–
2344, moscajos@csr.nih.gov.
Name of Committee: Center for Scientific
Review Special Emphasis Panel, Coxiella
Pathogenesis.
Date: August 19, 2005.
Time: 11 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone conference call).
Contact Person: Melody Mills, PhD,
Scientific Review Administrator, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3204,
MSC 7808, Bethesda, MD 20892. (301) 435–
0903, millsm@csr.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–396, 93.837–93.844, 93.846–
93.878, 93.892, 93.893, National Institutes of
Health, HHS)
Dated: July 27, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory
Committee Policy.
[FR Doc. 05–15246 Filed 8–2–05; 8:45 am]
BILLING CODE 4140–01–M
PO 00000
Frm 00119
Fmt 4703
Sfmt 4703
44671
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of Exclusive
License: Adaphostin as a Novel
Cancer Therapy
National Institutes of Health,
Public Health Service, HHS.
ACTION: Notice.
AGENCY:
SUMMARY: This is notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7(a)(1)(i), that the National
Institutes of Health, Department of
Health and Human Services, is
contemplating the grant of an exclusive
patent license to practice the inventions
embodied in:
1. E–013–1998/0–US–01,
‘‘Disubstituted Lavendustin A Analogs
and Pharmaceutical Compositions
Comprising the Analogs’’, by
Venkatachala Narayanan, Edward
Sausville, Kaur Gurmeet, Varma Ravi,
application number 60/076,330 (filed
February 27, 1998);
2. E–013–1998/0–PCT–02,
‘‘Disubstituted Lavendustin A Analogs
and Pharmaceutical Compositions
Comprising the Analogs’’, by
Venkatachala Narayanan, Edward
Sausville, Kaur Gurmeet, Varma Ravi,
application number PCT/US99/04002
(filed February 24, 1999);
3. E–013–1998/0–EP–03,
‘‘Disubstituted Lavendustin A Analogs
and Pharmaceutical Compositions
Comprising the Analogs’’, by
Venkatachala Narayanan, Edward
Sausville, Kaur Gurmeet, Varma Ravi,
application number 99910987.9 (filed
February 24, 1999);
4. E–013–1998/0–JP–04,
‘‘Disubstituted Lavendustin A Analogs
and Pharmaceutical Compositions
Comprising the Analogs’’, by
Venkatachala Narayanan, Edward
Sausville, Kaur Gurmeet, Varma Ravi,
application number 2000–533395 (filed
February 24, 1999);
5. E–013–1998/0–AU–05,
‘‘Disubstituted Lavendustin A Analogs
and Pharmaceutical Compositions
Comprising the Analogs’’, by
Venkatachala Narayanan, Edward
Sausville, Kaur Gurmeet, Varma Ravi,
patent number 760046 (filed February
24, 1999);
6. E–013–1998/0–CA–06,
‘‘Disubstituted Lavendustin A Analogs
and Pharmaceutical Compositions
Comprising the Analogs’’, by
Venkatachala Narayanan, Edward
Sausville, Kaur Gurmeet, Varma Ravi,
application number 60/076,330 (filed
February 24, 1999);
E:\FR\FM\03AUN1.SGM
03AUN1
Agencies
[Federal Register Volume 70, Number 148 (Wednesday, August 3, 2005)]
[Notices]
[Page 44671]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 05-15246]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Center for Scientific Review; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. Appendix 2), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), title 5
U.S.C., as amended. The grant applications and the discussions could
disclose confidential trade secrets or commercial property such as
patentable material, and personal information concerning individuals
associated with the grant applications, the disclosure of which would
constitute a clearly unwarranted invasion of personal privacy.
Name of Committee: Center for Scientific Review Special emphasis
Panel, Member Conflict: Tumor Cell Biology and Microenvironment.
Date: August 2, 2005.
Time: 11 a.m. to 1 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892. (Telephone conference call).
Contact Person: Sharon K. Gubanich, PhD, Scientific Review
Administrator, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 6204, MSC 7804. Bethesda, MD
20892. (301) 435-1767. gubanics@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific Review Special Emphasis
Panel, Hyperaccelerated Award/Mechanisms in Immunomodulation Trials.
Date: August 2, 2005.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive.
Bethesda, MD 20892. (Telephone conference call).
Contact Person: Samuel C. Edwards, PhD, Scientific Review
Administrator, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4200, MSC 7812, Bethesda, MD
20892. (301) 435-1767. edwardss@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific Review Special Emphasis
Panel, Dermatological Sciences Special Emphasis Panel.
Date: August 8, 2005.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive.
Bethesda, MD 20892. (Telephone conference call).
Contact Person: Aftab A. Ansari, PhD, Scientific Review
Administrator, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4108, MSC 7814, Bethesda, MD
20892. (301) 594-6376. ansaria@csr.nih.gov.
This notice is being published less than 15 days prior to the
meeting due to the timing limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific Review Special
Entamoeba Metabolism and Virulence.
Date: August 16, 2005.
Time: 1 p.m. to 2 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892. (Telephone conference call).
Contact Person: Joseph D. Mosca, PhD, Scientific Review
Administrator, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 5158, MSC 7808, Bethesda, MD
20892. (301) 435-2344, moscajos@csr.nih.gov.
Name of Committee: Center for Scientific Review Special Emphasis
Panel, Coxiella Pathogenesis.
Date: August 19, 2005.
Time: 11 a.m. to 12:30 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6701 Rockledge Drive,
Bethesda, MD 20892. (Telephone conference call).
Contact Person: Melody Mills, PhD, Scientific Review
Administrator, Center for Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3204, MSC 7808, Bethesda, MD
20892. (301) 435-0903, millsm@csr.nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.306,
Comparative Medicine; 93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393-396, 93.837-93.844, 93.846-93.878, 93.892, 93.893,
National Institutes of Health, HHS)
Dated: July 27, 2005.
Anthony M. Coelho, Jr.,
Acting Director, Office of Federal Advisory Committee Policy.
[FR Doc. 05-15246 Filed 8-2-05; 8:45 am]
BILLING CODE 4140-01-M